1h Free Analyst Time
The multi-cancer early detection market is forecasted to grow by USD 1.29 billion during 2024-2029, accelerating at a CAGR of 15.4% during the forecast period. The report on the multi-cancer early detection market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cancer prevalence, increased healthcare awareness, and growth in aging population.
The multi-cancer early detection market is segmented as below:
By Type
- Gene panel
- LDT
- Liquid biopsy
- Others
By End-user
- Hospitals
- Diagnostic laboratories
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the multi-cancer early detection market covers the following areas:
- Multi-Cancer Early Detection Market sizing
- Multi-Cancer Early Detection Market forecast
- Multi-Cancer Early Detection Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by End-user
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global multi-cancer early detection market: Adaptive Biotechnologies Corp., Burning Rock Biotech Ltd., EarlyDiagnostics, Elypta AB, Epigenomics AG, Exact Sciences Corp., F. Hoffmann La Roche Ltd., Freenome Holdings Inc., GRAIL Inc., Guardant Health Inc., Lucence Health Inc., Myriad Genetics Inc., Natera Inc., OncoCyte Corp, SeekIn Inc., Singlera Genomics Inc., and StageZero Life Sciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is focus on new product development."
According to the report, one of the major drivers for this market is the rising cancer prevalence.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptive Biotechnologies Corp.
- Burning Rock Biotech Ltd.
- EarlyDiagnostics
- Elypta AB
- Epigenomics AG
- Exact Sciences Corp.
- F. Hoffmann La Roche Ltd.
- Freenome Holdings Inc.
- GRAIL Inc.
- Guardant Health Inc.
- Lucence Health Inc.
- Myriad Genetics Inc.
- Natera Inc.
- OncoCyte Corp
- SeekIn Inc.
- Singlera Genomics Inc.
- StageZero Life Sciences Ltd.
